---
document_datetime: 2025-12-29 11:34:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zostavax.html
document_name: zostavax.html
version: success
processing_time: 0.1084319
conversion_datetime: 2025-12-30 08:54:47.207377
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zostavax

[RSS](/en/individual-human-medicine.xml/66356)

##### Withdrawn

This medicine's authorisation has been withdrawn

shingles (herpes zoster) vaccine (live) Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zostavax](#news-on)
- [More information on Zostavax](#more-information-on-zostavax-678)
- [More information on Zostavax](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 1 June 2025, the European Commission withdrew the marketing authorisation for Zostavax (shingles (herpes zoster) vaccine (live)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp &amp; Dohme B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Zostavax was granted marketing authorisation in the EU on 19 May 2006 for the prevention of herpes zoster and herpes zoster-related post-herpetic neuralgia in people 50 years of age or older. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2010. It was then granted unlimited validity in 2015. The product had not been marketed in the EU since 1 May 2025.

Zostavax : EPAR - Summary for the public

English (EN) (177.53 KB - PDF)

**First published:** 17/01/2007

**Last updated:** 11/06/2025

[View](/en/documents/overview/zostavax-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-448)

български (BG) (230.81 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/bg/documents/overview/zostavax-epar-summary-public_bg.pdf)

español (ES) (168.21 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/es/documents/overview/zostavax-epar-summary-public_es.pdf)

čeština (CS) (205.91 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/cs/documents/overview/zostavax-epar-summary-public_cs.pdf)

dansk (DA) (164.43 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/da/documents/overview/zostavax-epar-summary-public_da.pdf)

Deutsch (DE) (174.13 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/de/documents/overview/zostavax-epar-summary-public_de.pdf)

eesti keel (ET) (156.09 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/et/documents/overview/zostavax-epar-summary-public_et.pdf)

ελληνικά (EL) (243.93 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/el/documents/overview/zostavax-epar-summary-public_el.pdf)

français (FR) (169.59 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/fr/documents/overview/zostavax-epar-summary-public_fr.pdf)

hrvatski (HR) (196.63 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/hr/documents/overview/zostavax-epar-summary-public_hr.pdf)

italiano (IT) (166.28 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/it/documents/overview/zostavax-epar-summary-public_it.pdf)

latviešu valoda (LV) (208.31 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/lv/documents/overview/zostavax-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (209.21 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/lt/documents/overview/zostavax-epar-summary-public_lt.pdf)

magyar (HU) (195.85 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/hu/documents/overview/zostavax-epar-summary-public_hu.pdf)

Malti (MT) (223.68 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/mt/documents/overview/zostavax-epar-summary-public_mt.pdf)

Nederlands (NL) (171.11 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/nl/documents/overview/zostavax-epar-summary-public_nl.pdf)

polski (PL) (208.34 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/pl/documents/overview/zostavax-epar-summary-public_pl.pdf)

português (PT) (167.87 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/pt/documents/overview/zostavax-epar-summary-public_pt.pdf)

română (RO) (211.94 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/ro/documents/overview/zostavax-epar-summary-public_ro.pdf)

slovenčina (SK) (212.56 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/sk/documents/overview/zostavax-epar-summary-public_sk.pdf)

slovenščina (SL) (195.85 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/sl/documents/overview/zostavax-epar-summary-public_sl.pdf)

Suomi (FI) (158.04 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/fi/documents/overview/zostavax-epar-summary-public_fi.pdf)

svenska (SV) (176.01 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/sv/documents/overview/zostavax-epar-summary-public_sv.pdf)

## Product information

Zostavax : EPAR - Product Information

English (EN) (1.9 MB - PDF)

**First published:** 14/12/2009

**Last updated:** 11/06/2025

[View](/en/documents/product-information/zostavax-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-681)

български (BG) (2.44 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/bg/documents/product-information/zostavax-epar-product-information_bg.pdf)

español (ES) (1.94 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/es/documents/product-information/zostavax-epar-product-information_es.pdf)

čeština (CS) (2.31 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/cs/documents/product-information/zostavax-epar-product-information_cs.pdf)

dansk (DA) (1.94 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/da/documents/product-information/zostavax-epar-product-information_da.pdf)

Deutsch (DE) (2.18 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/de/documents/product-information/zostavax-epar-product-information_de.pdf)

eesti keel (ET) (1.83 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/et/documents/product-information/zostavax-epar-product-information_et.pdf)

ελληνικά (EL) (2.54 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/el/documents/product-information/zostavax-epar-product-information_el.pdf)

français (FR) (1.95 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/fr/documents/product-information/zostavax-epar-product-information_fr.pdf)

hrvatski (HR) (2.14 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/hr/documents/product-information/zostavax-epar-product-information_hr.pdf)

íslenska (IS) (1.81 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/is/documents/product-information/zostavax-epar-product-information_is.pdf)

italiano (IT) (2.13 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/it/documents/product-information/zostavax-epar-product-information_it.pdf)

latviešu valoda (LV) (2.16 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/lv/documents/product-information/zostavax-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.2 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/lt/documents/product-information/zostavax-epar-product-information_lt.pdf)

magyar (HU) (2.22 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/hu/documents/product-information/zostavax-epar-product-information_hu.pdf)

Malti (MT) (2.98 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/mt/documents/product-information/zostavax-epar-product-information_mt.pdf)

Nederlands (NL) (2.13 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/nl/documents/product-information/zostavax-epar-product-information_nl.pdf)

norsk (NO) (1.85 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/no/documents/product-information/zostavax-epar-product-information_no.pdf)

polski (PL) (2.49 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/pl/documents/product-information/zostavax-epar-product-information_pl.pdf)

português (PT) (2.04 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/pt/documents/product-information/zostavax-epar-product-information_pt.pdf)

română (RO) (2.35 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/ro/documents/product-information/zostavax-epar-product-information_ro.pdf)

slovenčina (SK) (2.29 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/sk/documents/product-information/zostavax-epar-product-information_sk.pdf)

slovenščina (SL) (2.08 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/sl/documents/product-information/zostavax-epar-product-information_sl.pdf)

Suomi (FI) (2.1 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/fi/documents/product-information/zostavax-epar-product-information_fi.pdf)

svenska (SV) (1.81 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

11/06/2025

[View](/sv/documents/product-information/zostavax-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0142/G 30/06/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zostavax : EPAR - All Authorised presentations

English (EN) (135.28 KB - PDF)

**First published:** 17/01/2007

**Last updated:** 11/06/2025

[View](/en/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-163)

български (BG) (169.85 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/bg/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_bg.pdf)

español (ES) (118.29 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/es/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_es.pdf)

čeština (CS) (131.37 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/cs/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (100.48 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/da/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (103.05 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/de/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (87.78 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/et/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (113.21 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/el/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_el.pdf)

français (FR) (100.71 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/fr/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (109.15 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/hr/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (91.16 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/is/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_is.pdf)

italiano (IT) (94.31 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/it/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (107.69 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/lv/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (109.5 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/lt/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (116.94 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/hu/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (155.65 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/mt/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (151.94 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/nl/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (103.92 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/no/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_no.pdf)

polski (PL) (116.05 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/pl/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_pl.pdf)

português (PT) (103.25 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/pt/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_pt.pdf)

română (RO) (116.67 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/ro/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (163.78 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/sk/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (121.43 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/sl/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (133.58 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/fi/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (101.75 KB - PDF)

**First published:**

17/01/2007

**Last updated:**

11/06/2025

[View](/sv/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zostavax Active substance varicella-zoster virus (live, attenuated) International non-proprietary name (INN) or common name shingles (herpes zoster) vaccine (live) Therapeutic area (MeSH)

- Herpes Zoster
- Immunization

Anatomical therapeutic chemical (ATC) code J07BK02

### Pharmacotherapeutic group

Viral vaccines

### Therapeutic indication

Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia.

Zostavax is indicated for immunisation of individuals 50 years of age or older.

## Authorisation details

EMA product number EMEA/H/C/000674 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Opinion adopted 23/03/2006 Marketing authorisation issued 19/05/2006 Withdrawal of marketing authorisation 01/06/2025 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zostavax : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.74 MB - PDF)

**First published:** 04/12/2009

**Last updated:** 11/06/2025

[View](/en/documents/procedural-steps-after/zostavax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zostavax-H-C-674-A20-0052 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/78658/2013

English (EN) (337.63 KB - PDF)

**First published:** 27/03/2013

**Last updated:** 11/06/2025

[View](/en/documents/variation-report/zostavax-h-c-674-a20-0052-epar-assessment-report-article-20_en.pdf)

Zostavax-H-C-674-II-0003 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (463.11 KB - PDF)

**First published:** 12/10/2007

**Last updated:** 11/06/2025

[View](/en/documents/scientific-discussion-variation/zostavax-h-c-674-ii-0003-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Zostavax : EPAR - Scientific Discussion

English (EN) (660.98 KB - PDF)

**First published:** 17/01/2007

**Last updated:** 11/06/2025

[View](/en/documents/scientific-discussion/zostavax-epar-scientific-discussion_en.pdf)

Zostavax : EPAR - Procedural steps taken before authorisation

English (EN) (123.29 KB - PDF)

**First published:** 17/01/2007

**Last updated:** 11/06/2025

[View](/en/documents/procedural-steps/zostavax-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Zostavax

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2012) 14/12/2012

#### More information on Zostavax

- [Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines](/en/medicines/human/referrals/monovalent-multivalent-measles-mumps-rubella-varicella-vaccines)

Zostavax: Product information as approved by the CHMP on 13 December 2012, pending endorsement by the European Commission

English (EN) (1.47 MB - PDF)

**First published:** 14/12/2012

**Last updated:** 11/06/2025

[View](/en/documents/referral/zostavax-product-information-approved-chmp-13-december-2012-pending-endorsement-european-commission_en.pdf)

#### More information on Zostavax

- [A retrospective matched cohort study on the association between herpes zoster vaccination and dementia and mild cognitive impairment using electronic health records (ZOSTER-122 AIML 222419) - post-authorisation study](https://catalogues.ema.europa.eu/study/108337)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 11/06/2025

## Share this page

[Back to top](#main-content)